Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells
Sign Up to like & getrecommendations! Published in 2018 at "OncoImmunology"
DOI: 10.1080/2162402x.2018.1438800
Abstract: ABSTRACT Interleukin-12 (IL12) (p35/p40 complex) is a heterodimeric cytokine with potent anti-tumor activity. However, its short serum half-life and high dose-related toxicities limit its clinical efficacy. Here, we constructed heterodimeric immunoglobulin Fc-fused mouse IL12 (mIL12)… read more here.
Keywords: il12; cd8 cells; mil12; memory cd8 ... See more keywords
Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression
Sign Up to like & getrecommendations! Published in 2023 at "Oncoimmunology"
DOI: 10.1080/2162402x.2023.2198185
Abstract: ABSTRACT The tumor microenvironment (TME) in ovarian cancer (OC) is characterized by immune suppression, due to an abundance of suppressive immune cells populations. To effectively enhance the activity of immune checkpoint inhibition (ICI), there is… read more here.
Keywords: cell; il12; cell induced; ovarian cancer ... See more keywords
First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-1512
Abstract: Purpose: The NHS-IL12 immunocytokine is composed of two IL12 heterodimers fused to the NHS76 antibody. Preclinical studies have shown that this antibody targets IL12 to regions of tumor necrosis by binding histones on free DNA… read more here.
Keywords: phase; il12; nhs il12; solid tumors ... See more keywords
Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-2819
Abstract: Systemic IL12 therapy has potent antitumor effects, but clinical delivery of this potent cytokine has been complicated by systemic toxicity. A novel strategy to deliver IL12 to the tumor microenvironment appears promising in a first-in-human… read more here.
Keywords: il12; delivery; place il12; right time ... See more keywords
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-0972
Abstract: Purpose: IL12 promotes adaptive type I immunity and has demonstrated antitumor efficacy, but systemic administration leads to severe adverse events (AE), including death. This pilot trial investigated safety, efficacy, and immunologic activity of intratumoral delivery… read more here.
Keywords: merkel cell; cell carcinoma; intratumoral delivery; il12 ... See more keywords
Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2019.01448
Abstract: IL12 is an immune-stimulatory cytokine for key immune cells including T cells and NK cells. However, systemic administration of IL12 has serious side effects that limit its clinical application in patients. Recently, synthetic Notch (synNotch)… read more here.
Keywords: synnotch receptor; il12; car; nk92 cells ... See more keywords